Ahmet Taner SÜMBÜL, Ali Murat SEDEF, Serkan GÖKÇAY, Züleyha ÇALIKUŞU, Aykut BAHÇECİ

The Prognostic Significance of Complete Response Rates in Patients with Extensive Stage Small Cell Lung Cancer

OBJECTIVESmall cell lung cancer (SCLC) is the most aggressive type of lung cancer. Platinum-etoposide chemotherapy combination is used as first line treatment. The aim of this trial is evaluate the effect of completeresponse rates and clinical features in patients with extensive stage (ES) SCLC.METHODSIn this retrospective study, a total of 117 patients from four different oncology centers in Turkey between2011 and 2017 were divided into 2 groups, namely, patients with complete response (group 1) and thosewith no complete response (group 2) after platin-etoposide combination therapy.RESULTSThe median age of the patients was 61 (range 38-81) years.The median follow-up time was 12 monthsand 95 (81%) patients died. Progression-free survival (PFS) and overall survival (OS) were estimated,respectively, as 8 and 13 months. Overall survival of group 1 patients was statistically significantly betterthan the group 2 (16 versus 10 months respectively and p=0.00). The overall survival of patients whohad late recurrent disease (>6 mo.) was statistically significantly better than the early ones (

PDF

___

1. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24(28):4539–44.
2. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, CA Cancer J Clin 2016;66(4):271–89.
3. Albain KS, Crowley JJ, Livingston RB. Long-term survival and toxicity in small cell lung cancer. Expanded Southwest Oncology Group experience. Chest 1991;99(6):1425–32.
4. Wang X, Teng F, Kong L, Yu J. Pretreatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer. OncoTargets Therapy 2016;9:5761–70.
5. Shao N, Cai Q. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer. Clin Transl Oncol 2015;17(10):772–8.
6. He Y, Wang Y, Boyle T, Ren S, Chan D, Rivard C, et al. Hepatic metastases is associated with poor efficacy of Erlotinib as 2nd/3rd line therapy in patients with lung Adenocarcinoma. Med Sci Monitor 2016;22:276–83.